Evidence map›Paper›PMID 36185441›Full record

ArticleFrontiers in bioengineering and biotechnology2022

Retinal organoids and microfluidic chip-based approaches to explore the retinitis pigmentosa with USH2A mutations.

Ting Su, Liying Liang, Lan Zhang, Jianing Wang, Luyin Chen, Caiying Su, Jixing Cao, Quan Yu, Shuai Deng, Hon Fai Chan and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. USH2A-Mutated Human Retinal Organoids Model Rod-Cone Dystrophy.Investigative ophthalmology & visual science · 2025
    Article
  6. Review
  7. Review
  8. Article
  9. Retinal Organoids: Innovative Tools for Understanding Retinal Degeneration.International journal of molecular sciences · 2025
    Review
  10. Review
  11. Review
  12. "ArmedFrontiers in cell and developmental biology · 2025
    Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. HGG advances · 2023
    Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ting SuDepartment of Ophthalmology, First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China.
Liying LiangDepartment of Ophthalmology, First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China.
Lan ZhangDepartment of Ophthalmology, First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China.
Jianing WangKey Laboratory for Regenerative Medicine, Ministry of Education, Jinan University, Guangzhou, China.
Luyin ChenKey Laboratory for Regenerative Medicine, Ministry of Education, Jinan University, Guangzhou, China.
Caiying SuDepartment of Ophthalmology, First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China.
Jixing CaoDepartment of Ophthalmology, First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China.
Quan YuCentric Laboratory, Medical College, Jinan University, Guangzhou, China.
Shuai DengInstitute for Tissue Engineering and Regenerative Medicine, Chinese University of Hong Kong, Hong Kong, China.
Hon Fai ChanInstitute for Tissue Engineering and Regenerative Medicine, Chinese University of Hong Kong, Hong Kong, China.
Shibo TangAier Eye Institute, Changsha, China.
Yonglong GuoDepartment of Ophthalmology, First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China.
Jiansu ChenInstitute of Ophthalmology, Medical College, Jinan University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retinitis pigmentosa (RP) is a leading cause of vision impairment and blindness worldwide, with limited medical treatment options. USH2A mutations are one of the most common causes of non-syndromic RP. In this study, we developed retinal organoids (ROs) and retinal pigment epithelium (RPE) cells from induced pluripotent stem cells (iPSCs) of RP patient to establish a sustainable

Indexed as

induced pluripoten stem cellsmicrofludic chipretinal organoidsretinitis pigmentosaUSH2A

Identifiers

PMID36185441
PMCPMC9524156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.